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Resveratrol effects on astrocyte function: relevance to
neurodegenerative diseases
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Abstract
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Inflammatory molecules have been implicated in the pathogenesis of neurodegenerative diseases
such as Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. Resveratrol is an antifungal compound found in the skins of red grapes and other fruits and nuts. We examined the
ability of resveratrol to inhibit lipopolysaccharide (LPS)-induced production of inflammatory
molecules from primary mouse astrocytes. Resveratrol inhibited LPS-induced production of nitric
oxide (NO); the cytokines tumor necrosis factor-alpha (TNF-α), interleukin 1-beta (IL-1β), and
IL-6; and the chemokine monocyte chemotactic protein-1 (MCP-1), which play critical roles in
innate immunity, by astrocytes. Resveratrol also suppressed astrocyte production of IL-12p40 and
IL-23, which are known to alter the phenotype of T cells involved in adaptive immunity. Finally
resveratrol inhibited astrocyte production of C-reactive protein (CRP), which plays a role in a
variety of chronic inflammatory disorders. Collectively, these studies suggest that resveratrol may
be an effective therapeutic agent in neurodegenerative diseases initiated or maintained by
inflammatory processes.
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1. Introduction
The role of inflammatory processes in the pathogenesis of neurodegenerative diseases is
well accepted but poorly understood [1]. Poorly controlled or chronic inflammatory
activation of microglia and astrocytes has been implicated in the development and
worsening of Alzheimer’s disease [2] Parkinson’s disease [3] multiple sclerosis [4], and
other neurodegenerative disorders [5].
Astrocytes, resident central nervous system (CNS) glial cells with multiple metabolic and
neurotransmission functions, have been implicated in the initiation and maintenance of
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neurodegenerative processes and, alternatively, purported to protect against those processes[3,6,7]. Among the potential mechanisms for astrocytes contribution to disease development
and progression, the effects of astrocyte responses to pathogens and pro-inflammatory
cytokines appear likely. These responses include the production of nitric oxide (NO) and
multiple cytokines and chemokines under the control of transcription factor nuclear factor
κβ (NF-κB). While these molecules are essential to normal immune function, chronically
high levels can interfere with normal function of the activated astrocyte and surrounding
cells of the CNS [5].
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Resveratrol, a naturally occurring phytogenic estrogen [8] found in the skin of grapes, red
wine, mulberries, and several types of nuts, possesses anti-inflammatory properties [9]. Our
study examines resveratrol’s ability to suppress the production of inflammation-mediating
molecules in primary astrocytes extracted from mice. Specifically, in LPS-induced
astrocytes, we find dose-dependent effects of resveratrol on NO, TNF-α, IL-1β, IL-6,
MCP-1, IL-12p40, IL-23, and CRP. Given the role that chronically elevated levels of these
molecules may play in neurodegeneration, these findings suggest resveratrol may be an
effective agent for preventing or treating neurodegenerative diseases initiated or maintained
by inflammatory processes.

2. Materials and methods
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Primary astrocyte cultures were obtained through a modification of the McCarthy and
deVellis protocol [10]. Briefly, cerebral cortices from 1–2 day-old C57BL/6 mice were
excised, meninges removed, and cortices minced into small pieces. Cells were separated by
trypsinization followed by trituration of cortical tissue. Cells were plated into tissue culture
flasks and allowed to grow to confluence (approximately 10 days) in DMEM media
containing 10% FBS, 1.4mM glutamine, and OPI media supplement (Sigma, St. Louis,
MO). Flasks were shaken overnight (200 rpm at 37°C) in a temperature controlled shaker to
loosen microglia and oligodendrocytes from the more adherent astrocytes. L-LME (0.1 mM)
was added to the cultures to eliminate any residual microglia. Using this procedure,
astrocyte cultures of greater than 95% purity were obtained as determined by
immunohistochemistry with antibodies prepared against GFAP for astrocytes and the lectin,
Griffonia simplicifolia (GSA) to measure contaminating microglia. Astrocytes were seeded
into 96-well plates. The following day, cultures were treated for 1 h with the indicated
concentrations of resveratrol followed by treatment for 24 h with 2μg/ml lipopolysaccharide
(LPS). Tissue culture supernatants and cells were collected for cell viability, nitrite, and
ELISA assays, which were conducted as we have described previously [11].
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3. Results
Resveratrol inhibited NO production in a dose-dependent manner (Figure 1A). Resveratrol
was not toxic to astrocytes in these studies as determined by MTT assays, indicating that
resveratrol suppression of NO by primary astrocytes was not due to astrocyte cell death
(Figure 1B).
LPS induced the production of inflammatory cytokines TNF-α (Figure 2A), IL-1β (Figure
2B), IL-6 (Figure 2C), and MCP-1 (Figure 2D) which are molecules that play critical roles
in innate immunity. In addition, resveratrol inhibited LPS induction of IL-12 (Figure 3A)
and IL-23 (Figure 3B), which are cytokines that are capable of altering the phenotype of T
cells that are critical to adaptive immunity. Finally, resveratrol suppressed LPS-induction of
CRP (Figure 4) by primary astrocytes, and CRP has been associated with a variety of
chronic inflammatory disorders. Resveratrol suppressed astrocyte production of these
inflammatory molecules in a dose-dependent manner. Collectively, these studies indicate
that resveratrol is effective in the suppression of a variety of pro-inflammatory molecules,
Biochem Biophys Res Commun. Author manuscript; available in PMC 2013 September 14.
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and thus may be effective in the treatment of neuroinflammatory and neurodegenerative
disorders.

4. Discussion
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Resveratrol has been shown to be neuroprotective against ischemia-induced injury [12], βamyloid-induced neurotoxicity [13], autoimmune-mediated injury [14], and various other
inflammation-mediated contributors to neuronal cell death and dysfunction [15]. Recent
studies have examined the effects of resveratrol on specific pro-inflammatory molecules in
the CNS, including NO [16] and cytokines under the influence of NF-κβ [17]. However,
most studies of relevance to neurodegenerative diseases have focused on resveratrol’s
effects in microglia and not astrocytes.
As reviewed by Quincozes-Santos & Gottfried [18], many of the neuroprotective effects of
resveratrol may be mediated by the compound’s modulatory actions on astrocytes.
Potentially protective actions in astrocytes include modulation of glutamate homeostasis,
modulation of ischemia-induced mitochondrial dysfunction, and suppression of acute and
chronic inflammation.
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A recent study indicated that resveratrol’s effects on mediators of inflammation may not be
identical in microglia and astrocytes. Lu and colleagues [19] found that resveratrol was a
more potent suppressor of TNF-α, IL-6, MCP-1, and NO production in mouse microglia
than in mouse astrocytes. They also found that resveratrol suppressed IL-1β production in
microglia but not in astrocytes. In contrast, we found that resveratrol significantly
suppressed IL-1β production at concentrations that did not affect the viability of astrocytes.
Interestingly, we also demonstrate for the first time that resveratrol inhibits LPS induction of
IL-12p40 and IL-23 by primary astrocytes. These cytokines play a critical role in the
differentiation of Th1 and Th17 cells known to contribute to the development of
experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis
[20]. Resveratrol suppresses the development of EAE [14] Our studies suggest that
resveratrol may suppress EAE, at least in part, through suppressing the development of Th1
and Th17 cells.
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The potential link between elevated serum levels of CRP and cardiopathology has received
significant attention. More recent studies suggest a potential link between high serum levels
of CRP with the presence and severity of AD [21] and PD [22,23,24], suggesting a role of
CRP in the pathogenesis of neurodegenerative diseases. A recent study indicates that proinflammatory cytokines induce CRP expression in primary microglia [25]. To the best of our
knowledge, the current study is the first demonstration of CRP expression by astrocytes and
the first to demonstrate that resveratrol inhibits LPS-induction of CRP production in these
cells. These studies suggest that resveratrol may suppress the development of
neurodegenerative diseases in part by suppressing CRP expression by astrocytes.
In summary, we demonstrated that resveratrol inhibits astrocyte production of several
molecules implicated in innate immunity and neurodegeneration. Furthermore, we
demonstrate for the first time that resveratrol suppresses the production of IL-12 and IL-23.
This suggests that resveratrol could suppress EAE by suppressing the development of Th1
and Th2 cells. Finally, we present the first evidence that resveratrol suppresses astrocyte
production of CRP. Collectively, these studies suggest that resveratrol may prove valuable
in the treatment of CNS diseases characterized by neuroinflammation and
neurodegeneration.
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•

Resveratrol inhibited astrocyte production of cytokines and chemokines.

•

Resveratrol inhibited production of C-reactive protein by astrocytes.

•

Resveratrol may be effective in the treatment of neurodegenerative diseases.

$watermark-text
$watermark-text
$watermark-text
Biochem Biophys Res Commun. Author manuscript; available in PMC 2013 September 14.

Wight et al.

Page 7

$watermark-text

Figure 1. Resveratrol suppresses production of nitrite in LPS-stimulated primary astrocytes
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Cells were pre-treated for 1h with the indicated concentrations of resveratrol (μg/ml). LPS
(2μg/ml) was added and cells were incubated for 24h. The concentration of nitrite was
measured using Greiss reaction (A). Cell viability was determined by MTT assay (B), and
resveratrol had no effect on cell viability. Values represent the mean +/− s.e.m. for triplicate
cultures. *** indicates p<.001 vs. LPS treated cultures. Data were analyzed by ANOVA
followed by a Bonferroni test to determine the significance of difference. These data are
representative of three independent experiments.
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Figure 2. Resveratrol suppresses production of inflammatory mediators by primary astrocytes

$watermark-text

Cells were pre-treated with resveratrol at the indicated concentration (μg/ml) for 1h, LPS
(2μg/ml) was added, and cells were incubated for 24h. Concentrations of inflammatory
mediators (TNF-α, A; IL-1β, B; IL-6, C; and MCP-1, D) in the culture medium were
determined by ELISA. Values represent the mean +/− s.e.m. for triplicate cultures. *
indicates p<.05, **indicates<.01, and ***indicates<.001 vs. LPS treated cultures. Data were
analyzed by ANOVA followed by a Bonferroni test to determine the significance of
difference. These data are representative of three independent experiments.
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Figure 3. Resveratrol suppresses production of IL-12 family cytokines by primary astrocytes

Cells were pre-treated with resveratrol at the indicated concentration (μg/ml) for 1h, LPS
(2μg/ml) was added, and cells were incubated for 24h. Concentrations of inflammatory
mediators (IL-12p40, A; and IL-23, B) in the culture medium were determined by ELISA.
Values represent the mean +/− s.e.m. for triplicate cultures. ***indicates p<.001 vs. LPS
treated cultures. Data were analyzed by ANOVA followed by a Bonferroni test to determine
the significance of difference. These data are representative of three independent
experiments.
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Figure 4. Resveratrol suppresses production of C-reactive protein by primary astrocytes
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Cells were pre-treated with resveratrol at the indicated concentration (μg/ml) for 1h, LPS
(2μg/ml) was added, and cells were incubated for 24h. Concentrations of CRP in the culture
medium were determined by ELISA. Values represent the mean +/− s.e.m. for triplicate
cultures. **indicates p<.01, and ***indicates<.001 vs. LPS treated cultures. Data were
analyzed by ANOVA followed by a Bonferroni test to determine the significance of
difference. These data are representative of three independent experiments.
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